Opens in a new tab
19 November 2026

The Paris Division Strikes Back

Le boulevard Montmartre la nuit, la chaussée mouillée reflétant les lumières des réverbères et des vitrines, avec une file de voitures à cheval entre deux rangées d’arbres.
Camille Pissarro, The Boulevard Montmartre at Night, 1897, National Gallery, London. Wikimedia Commons, public domain.

In Du Hast, But Not So Fast, I suggested that the apparent hegemony of a few UPC divisions would in time recede under the pressure of practice and appellate calibration. The plot seems to be moving faster than that. Like the late-act turn in The Empire Strikes Back, Paris steps back into the light with two matters that quietly reframe venue strategy at the UPC.

Paris, back in the frame

Two filings brought the Paris Local Division into focus over a genuinely hot summer for European patent law.

Merz v. Viatris (fampridine/Fampyra, SPC). A preliminary-injunction application was filed in Paris at the end of July 2025. Case management has been firm from the outset. Most notably, the court ordered Viatris to file a 70-page summary of its objection and Merz a 40-page reply on the basis of proportionality, expressly to keep the preliminary-injunction record usable and the timetable workable ahead of an October hearing. Procedure here is not mere housekeeping. It is the method by which the dispute is made adjudicable.

KeeeX v. OpenAI, Adobe, Truepic and the Coalition for Content Provenance and Authenticity (C2PA). On 17 June 2025, KeeeX filed a claim with the Paris Local Division in relation to implementations around the C2PA content-authenticity layer, notably against OpenAI, Adobe, Truepic, and the broad-based industry group C2PA, with a claim for multi-billion-euro damages. Whatever the final contours of the pleadings, the case squarely invites the court to articulate its approach to jurisdictional reach and standards-adjacent digital evidence.

Individually, each case matters on its own doctrinal axis: SPCs and proportionality for Merz, standards and platform-scale AI for KeeeX. Taken together, they test whether Paris can serve as a preferred venue for methodologically dense life-sciences injunctions and system-level digital disputes.

Are litigants really stepping out of the usual lanes?

The pull of the classic venues remains strong. What changes is that sophisticated plaintiffs are also experimenting with Paris when the narrative benefits from tight proportionality control, linguistic fit, and a bench willing to manage complex records under urgent timelines. The Merz file is instructive: rather than defaulting to a habitual venue, the claimant chose Paris to calibrate urgency, territorial scope and documentary discipline in a high-stakes launch window.

On KeeeX, the choice of Paris by a French innovator to confront platform actors and an industry coalition over a standards-layer technology is equally telling. This is less about contrarian forum selection than about identifying a venue perceived as ready to handle cross-border, tech-heavy disputes with procedural economy.

Will the trend hold, and will it spread beyond France?

Two cautious thoughts.

First, Paris will keep its screen time if it continues to deliver coherent, replicable case management and doctrine. Reasoned page limits grounded in proportionality, disciplined timetables and a willingness to decide jurisdictional questions without paralysis are precisely the habits that generate repeat filings. If parties can predict how Paris will frame urgency, scope and evidentiary load, Paris moves from experiment to habit.

Second, spillover beyond France is plausible where fact patterns fit. The Hague’s tradition of swift, technically literate interim relief and Milan’s growing momentum suggest that venue pluralism is not a slogan but a pathway. As local divisions articulate predictable approaches to proportionality and territorial reach, multi-node strategies across the UPC become easier to design.

None of this implies that the historic leaders fade. They remain central to the Court’s early jurisprudence. What changes is the map: the era of one obvious venue gives way to plural options, and Paris has signaled that it is prepared to host both disciplined SPC litigation and systemic technology cases.

Closing scene, not end credits

The Empire Strikes Back does not resolve the conflict. It rearranges the balance of forces. If Merz v. Viatris yields principled guidance on SPC-based preliminary relief, and if KeeeX prompts a serious engagement with standards-layer disputes in AI, we may look back at the summer of 2025 as the moment Paris rewrote its role in the UPC script, not by displacing anyone, but by making strategy genuinely multipolar.

Update (November 2026). Both matters have since produced significant decisions. Merz v. Viatris. The Paris Local Division refused the application for provisional measures on 21 November 2025, finding unreasonable delay under Rule 211.4 RoP. The UPC Court of Appeal set that order aside on 27 April 2026 (UPC_CoA_917/2025) and ordered Viatris Santé to refrain from marketing its fampridine generic in France until 25 July 2026 inclusive, the expiry date of SPC No. 13C0033. For the Court, the grant of a marketing authorisation does not in itself create an imminent infringement, whereas completion of the national procedures for health technology assessment, pricing and reimbursement may do so. The infringement action on the merits continues before the Paris Local Division, which on 15 October 2026 referred the counterclaim for revocation to the Paris Central Division, which has jurisdiction over the validity of the SPC. KeeeX. On 13 March 2026 the Court of Appeal held that the UPC has no jurisdiction over the alleged infringement of the Swiss, Spanish, British, Irish, Norwegian and Polish parts of the patent, setting aside on that point the Local Division order of 27 November 2025. Then, in a decision on the merits of 17 November 2026 (in French), the Paris Local Division declared invalid and revoked all asserted claims of EP 2 949 070, held all requests to amend inadmissible, dismissed all infringement claims and ordered KeeeX to bear the costs of the proceedings. The decision may be appealed within two months of its service. Paris has thus ruled on the merits in both files, and the Court of Appeal has clarified when urgency starts to run in the first and where long-arm jurisdiction stops in the second.

What the two files change for your decisions

For a pharmaceutical company holding a French SPC, or a generic company preparing a launch, Merz v. Viatris sets a concrete marker. The time to seek provisional measures before the UPC runs from when the right holder had, or should have had with due diligence, the necessary facts and evidence. Completion of pricing and reimbursement may mark that moment, whereas a marketing authorisation alone does not. Right holders should therefore track those steps and date precisely what they learn, and generic companies should measure what their own steps reveal. For a technology company considering suing defendants established outside UPC states, KeeeX calls for three checks before choosing Paris. Jurisdiction as the court of the place of the harmful event does not extend to infringement in a state that is not party to the UPC Agreement. A counterclaim for revocation can take down every asserted claim. And the description cannot be rewritten to give the patent a new meaning. Auditing validity and settling the claim set before filing is a prerequisite, not a precaution.

Dhenne Avocats acts before the Paris Local Division of the UPC and the French courts in patent and SPC disputes, including urgent proceedings. Contact the firm.

This article is an adaptation of an analysis by Matthieu Dhenne originally published on Kluwer Patent Blog on 25 September 2025: The Paris Division Strikes Back.

Author : Dhenne Avocats.